2006

研究業績

Papers (English)

Original papers

1. Asaka T, Yokoji H, Ito J, Yamaguchi K, Matsushima A. Autosomal recessive ataxia with peripheral neuropathy and elevated AFP: Novel mutations in SETX. Neurology 66:1580-1581, 2006

2. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol 13:655-658, 2006

3. Ishida C, Sakajiri K, Yoshita M, Joutel A, Riant F, Yamada M. CADASIL with a novel mutation in exon 7 of Notch3 gene (C388Y). Intern Med 45:981-985, 2006

4. Iwasaki Y, Iijima M, Kimura S, Yoshida M, Hashizume Y, Yamada M, Kitamoto T, Sobue G. Autopsy case of sporadic Creutzfeldt-Jakob disease presenting with signs suggestive of brainstem and spinal cord involvement. Neuropathology 26:550-556, 2006

5. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175: 107-117, 2006

6. Maruta T, Dolimbek BZ, Aoki KR, Atassi MZ. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes. A new assay for blocking and non-blocking antibodies. J Neurosci Methods 151:90-96, 2006

7. Maruta T, Komai K, Takamori M, Yamada M. Voglibose inhibits postprandial hypotension in neurological disorders and elderly people. Neurology 66:1432-1434, 2006

8. Maruta T, Oshima M, Deitiker PR, Ohtani M, Atassi MZ. Use of Alum and Inactive Bordetella pertussis for Generation of Antibodies Against Synthetic Peptides in Mice. Immunol Invest 35:137-148, 2006

9.Murakami H, Kawahara N, Yahata T, Yokoyama K, Komai K, Tomita K. Radiation myelopathy after radioactive iodine therapy for spine metastasis. Br J Radiol 79:e45-49, 2006

10. Nozaki I, Hamaguchi T, Komai K, Yamada M. Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 77:1094-1095, 2006

11. Nozaki I, Hamaguchi T, Noguchi-Shinohara M, Ono K, Shirasaki H, Komai K, Kitamoto T, Yamada M. The MM2-cortical form of sporadic Creutzfeldt-Jakob disease presenting with visual disturbance. Neurology 67:531-533, 2006

12. Ono K, Hasegawa K, Naiki H, Yamada M. Anti-parkinson agents have anti-amyloidogenic activity for Alzheimer’s β-amyloid fibrils in vitro. Neurochem Int 48:275-285, 2006

13. Ono K, Hirohata M, Yamada M. α-lipoic acid exhibits anti-amyloidogenecity for β-amyloid fibrils in vitro. Biochem Biophys Res Commun 341:1046-1052, 2006

14. Ono K, Noguchi-Shinohara M, Samuraki M, Matsumoto Y, Yanase D, Iwasa K, Naiki H,
Yamada M. Blood-borne factors inhibit Alzheimer’s β-amyloid fibril formation in vitro. Exp Neurol 202:579-583, 2006

15. Ono K, Noguchi-Shinohara M, Yoshita M, Naiki H, Yamada M. Cerebrospinal fluid of Alzheimer’s disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitro. Exp Neurol 203:579-583, 2006

16. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. J Neurochem 97:105-115, 2006

17. Oshima M*, Maruta T*, Ohtani M, Deitiker PR, Mosier D, Atassi MZ. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol 171:8-16, 2006 *Joint First Authorship.

18. Pittrock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 81:1207-14, 2006

19. Sakai K, Piao YS, Kikugawa K, Ohara S, Hasegawa M, Takano H, Fukase M, Nishizawa M, Kakita A, Takahashi H. Corticobasal degeneration with focal, massive tau accumulation in the subcortical white matter astrocytes. Acta Neuropathol 112:341-348, 2006

20. Sakai K, Yamada M, Sato T, Yamada M, Tsuji S, Takahashi H. Neuronal atrophy and synaptic alteration in a model mouse of dentatorubral-pallidoluysian atrophy. Brain 129:2353-2362, 2006

21. Stagi M, Gorlovoy M, Larionov S, Takahashi K, and Neumann H. Unloading kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-terminal kinase pathway. FASEB J 20:2573-2575, 2006

22. Yamada M on behalf of the Variant CJD Working Group, CJD Surveillance Committee, Japan. The first Japanese case of variant Creutzfeldt-Jakob disease showing periodic electroencephalogram. Lancet 36:874, 2006

23. Yoshikawa H, Sato K, Edahiro S, Furukawa Y, Maruta T, Iwasa K, Watanabe H, Takaoka S, Suzuki Y, Takamori M, Yamada M. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J Neuroimmunol 175:169-175, 2006

24. Yoshita M, Fletcher E, Harvey D, Martinez O, Ortega M, Reed BR, Mungas DM, DeCarli CS. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 67:2192-2198, 2006

25. Yoshita M, Ishida C, Yanase D, Yamada M. Immunoglobulin light-chain (AL) amyloidosis with myasthenic symptoms and echocardiographic features of dilated cardiomyopathy. Intern Med 45:159-162, 2006

26. Yoshita M, Taki J, Yokoyamada K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K,
Yamada M. Value of Iodine-123 MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850-1854, 2006

27. Yoshita M, Yamada M. Allodynia in the flank after thalamic stroke. J Clin Neurosci 13:288-291, 2006

Reviews

1. Hamaguchi T, Ono K, Yamada M. Anti-amyloidogenic therapies: Strategies for prevention and treatment of Alzheimer’s disease. Cell Mol Life Sci 63:1538-1552, 2006

2. Ono K, Hamaguchi T, Naiki H, Yamada M. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer’s disease. Biochim Biophys Acta (Molecular Basis of Disease) 1762:575-586, 2006

3. Ono K, Naiki H, Yamada M. The development of preventives and therapeutics for Alzheimer’s disease that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβ. Curr Pharmac Design 12:4357-4375, 2006

Book

1. Takamori M. Antibodies to muscle-specific tyrosine kinase and ryanodine recepter seronegative myasthenia gravis. In:Current Topics in Peptide & Protein Research 7:11-16, 2007 (Trivandrum:Reseach Trends Publishers)

2. Yamada M, Noguchi-Shinohara M, Hamaguchi T, Nakamura Y, Kitamoto T, Sato T, Mizusawa H. Creutzfeldt-Jakob disease surveillance in Japan. In: Iqbal K, Winblad B, Avila J, ed. Alzheimer’s Disease: New Advances. Bologna, Medimond, pp31-34, 2006

Presentations (International meeting)

Invited lectures

1. Ono K. The molecular interactions of Aβ protein with antioxidant compounds, as well as some biological molecules in vitro. UCLA Neurology Seminar. Los Angeles, November 10, 2006

2. Takamori M. Tacrolimus (FK506) acts on calcium-release and-influx channels to compensate for myasthenic weakness. Evening Seminar in the 8th International Congress of Neuroimmunology. Nagoya, October 16,2006

3. Yamada M, Yoshita M, Noguchi-Shinohara M, Ono K. Clinical Diagnosis of DLB :123I-MIBG Myocardial Scintigraphy is Useful Even in Patients Without Parkinsonism. The 4th International Workshop on DLB and PDD. Yokohama, November 2-4, 2006

4. Yamada M, Nakamura Y, Akino K. CJD Surveillance in Japan: plaque and non-plaque types of dural graft associated CJD. European and Associated Countries Collaborative CJD Surveillance Group. Slovenia, May 4-6, 2006

5. Yamada M. Prion diseases in Japan. Neuroscience Seminar, Institute for Clinical Neurology Medical University of Vienna. Vienna, July 14, 2006

6. Yoshikawa H. Current Status and Future Direction of Therapy for MG in Japan (Keynote Lecture). XVI International Neuro-ophthalmology Society Meeting, Tokyo. November 29-December 2, 2006.

7. Yoshikawa H. IL-12 p40 and its antibody are specific marker for myasthenia gravis with thymoma. Comparative study with IL-12 p70 antibody and ryanodine receptor antibody. New Treatment Strategy of Myasthenia Gravis ?Basic researches and Clinical experiences of Tacrolimus in Japan- The 8th International Congress of Neuroimmunology Evening Seminar. Nagoya, October 16, 2006.

Presentations

1. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-Inflammatory drugs have anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. The 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, July 15-20, 2006

2. Ishida C, Makifuchi T, Saiki S, Hirose G, Yamada M. An autopsied case of autosomal-dominant chorea-acanthocytosis. Third International Neuroacanthocytosis Symposium. Kyoto, October 28, 2006

3. Maruta T, Yoshikawa H, Furukawa Y, Iwasa K, Yamada M. A new sandwich ELISA method to detect antibodies against native form of ryanodine receptor. The 8th International Congress of Neuroimmunology. Nagoya, Japan, October 15-19, 2006

4. Mosier DR. Jha S, Xu K, Maruta T, Oshima M, Atassi MZ, Hoch W. Myasthenia Gravis Induced in Mice by Immunization with the Extracellular Domain of Rat Muscle-Specific Kinase (MuSK). The 58th Annual Meeting of the American Academy of Neurology. San Diego, CA, April 5, 2006

5. Ono K, Noguchi-Shinohara M, Samuraki M, Matsumoto Y, Yanase D, Iwasa K, Naiki H. Cerebrospinal fluid and plasma of Alzheimer patients promote β-amyloid fibril formation in vitro. Abstracts from ?th International Symposium on Amyloidosis. Boston, November 5-9, 2006

6. Ono K, Nogutchi M, Matsumoto Y, Yanase D, Iwasa K, Naiki H, Yamada M. Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro. The 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, July 15-20, 2006

7. Ono K, Yamada M. Potent anti-fibrillogenic and fibril-destabilizing effects of antioxidant compounds for α-synuclein. The 4th International Workshop on DLB and PDD. Yokohama, November 2-4, 2006

8. Prabhakaran S, Wright C, Yoshita M, DeCarli C, Sacco R. Silent infarcts in the Northern Manhattan Study: Prevalence and risk factors. 58th AAN Annual Meeting at San Diego, April 1-8, 2006 (NEUROLOGY 66 (5): 318-318 Suppl. 2)

9. Sakai K, Piao YS, Kikugawa K, Ohara S, Hasegawa M, Takano H, Fukase M, Nishizawa M, Kakita A, Takahashi H. Corticobasal degeneration with focal, massive tau accumulation in the subcortical astrocytes. 10th International Congress of Parkinson’s disease and Movement Disorders. Kyoto, October 28-November 2, 2006

10. Sakai K, Yamada M, Sato T, Yamada M, Tsuji S, Takahashi H. Neuronal atrophy and synaptic alteration in a mouse model of DRPLA. 16th International Congress of Neuropathology. San Fransisco, September 10-15, 2006

11. Samuraki M, Matsunari I, Chen W, Yajima K, Yanase D, Fujikawa A, Takeda N, Nishimura S, Matsuda H, Yamada M. FDG PET in patients with mild Alzheimer’s disease before and after correction for cortical atrophy. The Society of Nuclear Medicine 53rd Annual Meeting. San Diego, June 3-7, 2006

12. Takahashi K, Rochford CDR, Neumann H. Impaired clearance of apoptotic neurons by lack of microglial TREM2 signaling. The 8th International Conference of Neuroimmunology. Nagoya, October 16-19, 2006.

13. Takahashi K, Prinz M, and Neumann H. Clearance of tissue debris by TREM2-transduced myeloid cells promotes recovery of experimental autoimmune encephalomyelitis. The 8th International Conference of Neuroimmunology. Nagoya, Oct 16-19, 2006.

14. Takamori M. Antibodies to presynaptic receptors acting for synaptic plasticity in myasthenias.Symposium on Myasthenia Gravis and Myasthenic Syndrome in the 8th International Congress of Neuroimmunology. Nagoya, October17, 2006

15. Yamada M, Shinohara M, Hamaguchi T, Nakamura Y, Kitamoto T, Sato T, Mizusawa H. Creutzfeldt-Jakob Disease (CJD) Surveillance in Japan: Two Distinct subtypes of CJD associated with cadaveric dura mater graft and the first Japanese case of variant CJD. The 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, July 15-20, 2006

16. Yoshikawa H, Sato K, Edahiro S, Furukawa Y, Maruta T, Iwasa K, Watanabe H, Takaoka S, Suzuki Y, Takamori M, Yamada M. Elevation of IL-12 p40 and its antibody is a specific serum marker for myasthenia gravis with thymoma. The 8th International Congress of Neuroimmunology. Nagoya, October 15-19, 2006

17. Yoshita M, Fletcher E, Martinez O, Ortega M, Reed B, Mungas D, DeCarli C. Extent and distribution of white matter hyperintensities in normal aging, mild cognitive impairment and dementia. 58th AAN Annual Meeting at San Diego, April 1-8, 2006 (Neurology 66 (5): A106-A107 Suppl. 2, 2006)